Oral Solid dosage (OSD) Contract Manufacturing Market to Grow with a CAGR of 6.24% through 2028

Increasing demand of generic drugs are expected to drive the Global Oral Solid dosage (OSD) Contract Manufacturing Market in the forecast period 2024-2028.

According to TechSci Research report, “Oral Solid dosage (OSD) Contract Manufacturing Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Oral Solid dosage (OSD) Contract Manufacturing Market stood at USD 33.45 billion in 2022 and is anticipated to grow with a CAGR of 6.24% in the forecast period, 2024-2028. The demand for personalized medical solutions is increasing. Outsourcing OSD manufacturing allows pharmaceutical firms to focus on their core strengths, such as research, development, and marketing, while leaving manufacturing processes to specialized experts. Reputable OSD CMOs have in-depth knowledge of regulatory requirements and adhere to strict quality standards, reducing regulatory risks for their clients. CMOs offer flexibility in production scale, from small batches for clinical trials to large-scale commercial manufacturing, allowing pharmaceutical companies to adapt to market demands efficiently. CMOs often have streamlined processes and established infrastructure, enabling quicker product development and market entry. Pharmaceutical companies can leverage the global presence of CMOs to access new markets and navigate international regulatory complexities. OSD CMOs offer a wide range of formulation development and manufacturing services, including controlled release, immediate release, and oral sustained-release dosage forms. Advances in pharmaceutical manufacturing technologies and analytical tools have improved the efficiency and capabilities of OSD contract manufacturing. A growing pipeline of new pharmaceutical products, including generic drugs and novel therapies, drives demand for OSD contract manufacturing services. Outsourcing manufacturing reduces the capital investment and risks associated with building and maintaining in-house production facilities.

Oral Solid Dosage (OSD) Contract Manufacturing offers several advantages and applications within the pharmaceutical industry. One key advantage is cost-effectiveness. Pharmaceutical companies can reduce capital expenditures by outsourcing OSD production to specialized Contract Manufacturing Organizations (CMOs) that have already invested in state-of-the-art facilities and equipment, leading to significant cost savings. Additionally, OSD CMOs often benefit from economies of scale, enabling efficient production at competitive prices.

Another advantage is expertise. OSD CMOs possess extensive knowledge and experience in the formulation and production of various solid dosage forms, ensuring product quality and compliance with regulatory standards. This expertise is particularly beneficial for complex formulations, controlled-release drugs, and biopharmaceuticals, where precision and specialized knowledge are critical.

Furthermore, OSD contract manufacturing offers flexibility and scalability. Pharmaceutical companies can easily adjust production volumes according to market demands, avoiding excess inventory costs and production bottlenecks. This flexibility is crucial for both small-scale clinical trials and large-scale commercial manufacturing.

Applications of OSD contract manufacturing encompass a wide range of solid dosage forms, including tablets, capsules, powders, and granules. These dosage forms can accommodate various drug types, from over-the-counter medications and generic drugs to specialized formulations for specific therapeutic needs. OSD CMOs can produce both immediate-release and extended-release formulations, enabling the development of customized drug delivery systems. Additionally, they play a pivotal role in manufacturing high-potency drugs, combination therapies, and personalized medicine products, meeting the diverse needs of the pharmaceutical industry while maintaining cost-efficiency and quality standards.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Oral Solid dosage (OSD) Contract Manufacturing Market.”

The Global Oral Solid Dosage (OSD) Contract Manufacturing Market is driven by several key factors that have been instrumental in its growth and significance. Firstly, the pharmaceutical industry's increasing focus on cost-efficiency is a major driver. Outsourcing OSD manufacturing to specialized Contract Manufacturing Organizations (CMOs) allows pharmaceutical companies to reduce capital expenditures on production facilities and leverage the cost-effective infrastructure of CMOs. Secondly, the demand for specialized expertise is driving market growth. OSD CMOs offer extensive knowledge in formulation development, process optimization, and regulatory compliance, which is especially critical for complex drug formulations and biopharmaceuticals. Thirdly, the rise in complex drug formulations, including controlled-release and biologic-based drugs, has boosted the demand for OSD contract manufacturing services. These formulations require specialized equipment and technologies that CMOs can provide. Moreover, the globalization of pharmaceutical markets and the need for compliance with diverse regulatory standards drive pharmaceutical companies to partner with OSD CMOs with robust regulatory expertise. Additionally, the ongoing trend toward personalized medicine and niche drug products necessitates flexible and agile OSD manufacturing capabilities. Lastly, advancements in manufacturing technologies and the adoption of sustainable and eco-friendly practices are contributing to the growth of the OSD Contract Manufacturing Market, as companies seek partners with state-of-the-art facilities and green manufacturing capabilities.

The Global Oral Solid dosage (OSD) Contract Manufacturing Market is segmented into product, end user, regional distribution, and company.

Based on product, the market is segmented into Capsules, Tablets, Powders, Granules, and Other. The Tablets is expected to rise in the forecast period. This is attributed due to factors like ease of manufacturing, stable shelf life, accurate dosing, and patient familiarity. Tablets are cost-effective to produce, offer precise drug delivery, and are preferred by patients, making them a popular choice for pharmaceutical companies and consumers alike.

Based on end user, the market is segmented into Large-size companies, Small & medium size companies, Startups and generic pharmaceutical companies. The Large-size companies segment was dominated the market in 2022. This is due to their extensive resources, established infrastructure, and diversified product portfolios. They have the financial strength for research, innovation, and acquisitions. This allows them to secure contracts, invest in advanced technologies, navigate regulatory complexities, and meet diverse market demands more effectively than smaller entities, startups, or generic pharmaceutical companies.

Major companies operating in Global Oral Solid dosage (OSD) Contract Manufacturing Market are:

• AbbVie Inc.
• Acino International AG
• Aenova Holding GmbH
• Beximco Pharmaceuticals Ltd
• Boehringer Ingelheim International GmbH
• Catalent Inc.
• Corden Pharma International GmbH,
• PerkinElmer Inc.
• Pyramid Laboratories Inc.
• Siegfried AG

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The Global Oral Solid Dosage (OSD) Contract Manufacturing Market is driven by several key factors. The pharmaceutical companies seek cost-efficiency by outsourcing OSD production to specialized Contract Manufacturing Organizations (CMOs), reducing capital expenditure and operational costs. The growing complexity of drug formulations, including biopharmaceuticals and controlled-release dosage forms, drives demand for CMOs with specialized expertise and advanced technologies. The stringent regulatory requirements necessitate partnerships with OSD CMOs known for their compliance and quality assurance capabilities. The trend towards personalized medicine and specialty drugs fuels the need for flexible and agile manufacturing solutions. Additionally, the environmental sustainability initiatives drive the adoption of green manufacturing practices, enhancing OSD CMOs' appeal. Also, the pursuit of operational efficiency and risk mitigation in the pharmaceutical supply chain, especially in the face of global disruptions, reinforces the importance of OSD contract manufacturing. These drivers collectively underscore the pivotal role of OSD CMOs in the pharmaceutical industry's quest for cost-effective, high-quality, and sustainable oral solid dosage solutions” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Oral Solid dosage (OSD) Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product (Tablets, Capsules, Powders, Granules, Others), By End User (Large-size companies, Small & medium size companies, Startups and generic pharmaceutical companies), By Region and Competition” has evaluated the future growth potential of Global Oral Solid dosage (OSD) Contract Manufacturing Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Oral Solid dosage (OSD) Contract Manufacturing Market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: www.techsciresearch.com